Esperite N.V. (ESP) announces additional information on envisaged financing

                      

                                                    

ESPERITE N.V. (ESP) announces additional information on envisaged financing

Zutphen, The Netherlands - 29 August 2016

Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announced in its press release of 23 August 2016 that it prepares for a significant external funding before year end to which the main shareholder will contribute along with potential other investors.

Esperite announces that the future financing is expected to consist of an equity raising and issuance of convertible bonds by means of a private placement. 

The number of new shares to be issued will not exceed 20% of the currently issued share capital and hence be within the authority that has been granted by the shareholders to the board of directors during the annual general meeting of shareholders of 9 June 2016.

The convertible bonds would be following the same principles previously used by the company. 

About ESPERITE

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

To learn more about the ESPERITE Group, or to book an interview with CEO Frederic Amar: [phone] - [e-mail] or visit the websites at www.esperite.com,  www.genoma.com and www.cryo-save.com.

PR ESPERITE additional financing

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via Globenewswire